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Evolutionseveral studies have reported that thrombopoietin (THPO) presents several
alternative splicing products that differ from the full-length protein in its 5′ UTR, N- or C-terminal regions.
Most of these splice variants are evolutionarily conserved and have been detected in different tissues as well
as in cell lines. Although the possible functions of the THPO isoforms are still elusive, different clues link
them to the peculiar mechanism that regulates THPO production. Moreover, novel ﬁelds to explore possible
roles of the THPO variants are opened by observations that this hormone can inﬂuence the formation of
hematopoietic progenitors and its expression occurs in some tumors as well as in tissues not directly related
to the thrombopoiesis. In this review, we summarize the structure and functions of THPO through the
published evidence on its splicing isoforms and discuss about their involvement with physiopathologic
phenomena.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Thrombopoietin (THPO) is the major cytokine that regulates
platelet production. This factor controls the proliferation as well as
differentiation of megakaryocyte progenitor cells and is essential for
the production and maintenance of normal levels of thrombopoiesis
[1,2]. The major sources of THPO production are liver (in hepatocytes),
kidney (in convoluted tubular cells), bone marrow (in stromal cells)
and spleen [3–5]. THPO gene expression has also been detected in
skeletal muscle, ovary, testis and fetal lung [3,6–9]. Moreover, this
cytokine is produced also in the central nervous system (CNS) where
its generation appears to be locally restricted [10–12]. Five indepen-
dent groups cloned the gene of THPO in 1994 [1,13–16]. It is located on
chromosome 3q27 [6,17] and codiﬁes for a glycoprotein consisting of
353 amino acids and molecular weight of 30kDa. Structurally, the
mature THPO presents two domains.
The crystal structure of the functional domain of human THPO
(hTPO(163)), consisting of the N-terminal 163 amino acids, has been
determined [18,19]. There is an amino-terminal four helical bundle
domain (residues 1–152) that has receptor-binding ability, signaling
activity and supports cellular proliferation [20–22]. Then, there is a
carboxyl-terminal domain (residues 153–335) that does not share
homology with any known proteins and, although its deletion doesPathology, University of Trieste,
12; fax: +39 040 226555.
l rights reserved.not affect the activity of the protein in vitro, can enhance the secretion
of the molecule[20,23–25 and control the THPO bioavailability after
parenteral administration [26].
Dysregulation of THPO expression has been implicated in
cardiovascular diseases and blood disorders. The screening of the
whole THPO gene for SNPs led to identify ﬁve variants: g.1796CNT
within the 5′ UTR; g.4830CNA and g.4877ANC within intron 5;
g.5713ANG and g.6160ANT in the 3′ UTR [27]. Moreover, this study
showed that the frequency of at least one common polymorphism
(g.4830C) was found to be signiﬁcantly higher in young male Swedish
myocardial infarction survivors, compared with the controls [27].
In physiological conditions, the expression of THPO protein is very
inefﬁcient. The translation of THPOmRNA is inhibited by the presence
of upstream translational start codons (uAUG) located in the 5′ UTR of
the THPO mRNA. Interestingly, familial essential thrombocythaemia
(ET), an autosomal-dominant disorder which results in increased
levels of THPO, was found to be caused by mutations in the 5′
untranslated region (5′UTR) that remove or neutralize upstreamOpen
Reading Frames (uORF) [28–30]. The ﬁrst two alterations were a single
nucleotide deletion (c.-48_-47delG) and a substitution (c.-30GNT)
[28,30]. In vitro experiments showed that the identiﬁed mutations
increase THPO production through the loss of translational inhibition
that peculiarly controls the expression of THPO mRNA. The third
variationwas a splice donor site mutationwithin intron 3 (c.13+1GNC)
[29]. This alteration was found to generate THPO mRNA species with
shortened 5′ UTR that are more efﬁciently translated and lead to
thrombocythaemia because of the systemic overproduction of the
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skipping and intron 3 retention and occurs in a region of the THPO
gene that can undergo alternative splicing. Interestingly, since the
initial cloning, evidences were gathered indicating that the human
THPO gene can generate several splice variants. This review is
intended to provide a current picture concerning the structure and
functions of THPO through the published evidence on its splicing
isoforms, and to discuss about their potential implications with
physiopathologic events.
2. Alternative splicing of C-terminus of THPO limits the
bioavailability of THPO variants
Human THPO is alternatively spliced in a complex pattern, gener-
ating up to six variants of mRNA, by the use of four alternative 3′ splice
sites and an internal alternative 5′ splice site. In addition to the full-
length cDNA (THPO-1), two variants were initially described [6,31].
THPO-2 has a deletion of 12 nucleotides at the beginning of exon 6 but
maintains the same reading frame. THPO-3 is peculiar because it is
produced by splicing out 116 nucleotides of exon 6. Other isoforms
have been then identiﬁed, carrying deletions of 197 nt (THPO-4) and
128 nt (THPO-5) or insertion of 60 nt (THPO-6), respectively (Fig. 1).
On one hand, molecular investigations on the alternative splicing
of THPO-3, THPO-2, THPO-4, and THPO-6 variants have evidenced that
their expression can be regulated positively or negatively by the
presence of upstream introns [32]. On the other hand, THPO
alternative splicing is also potentially associated with cardiovascular
diseases. In fact, studies on THPO SNPs have found that the g.4830A
variant is associated with a signiﬁcant increase in production of the
THPO-3 versus THPO-1 transcript [27,33]. Therefore, the individuals
carrying the g.4830A allele might present a lower thrombotic risk in
acute coronary syndromes because of a reduced secretion of active
cytokine.
Interestingly, the structure of the THPO intron 6 and exon 7 is
highly conserved among ﬁve orthologue vertebrates' genes (human,
macaca, mouse, rat and cow) and it is apparent that also splicing
isoforms are likewise conserved. In fact, nine THPO isoforms of the lastFig. 1. Alternative RNA splicing patterns identiﬁed for human THPO. The regions of intron 6 an
sequence of each splicing variant is also shown.exon have been isolated in mouse and most of them overlap with
those detected in human [6,34,35]. There are also indications that
THPO-2 is conserved in pigs [6], and our searches in EST database have
revealed the conservation of THPO-3 variant in rat (Genbank accession
number CB725221). The high degree of homology of the gene
sequence among different species suggests that also most of the
splice isoforms of the C-terminal can be conserved through the
evolution. In mature THPO, the part of exon 7 undergoing alternative
splicing codiﬁes for the last 40 residues of the EPO-cytokine domain
that includes three potential O-glycosylation sites (p.T157, p.T158
and p.S163), one potential N-glycosylation sequence (p.N176-RT) and
p.C151 that is involved in disulﬁde bridgingwith p.C7 [1,36]. The THPO
glycan domain (TGD, that includes the carboxy-terminal end) has
been found to enhance secretion of the protein and its action in cis can
inhibit slightly the cytokine activity[20,23–25]. Interestingly, it has
also been shown that the TGD can modulate in trans the efﬁciency of
THPO processing working as an inter-molecular chaperone [24]. In
principle, the alternative splicing that alters this portion of themolecule
can modify its biological properties. Indeed, functional studies have
shown thatmouse THPO-4might retain a biological activity comparable
to that of the THPO-1 [37] but it is not secreted efﬁciently, likewise
THPO-2 and THPO-3 isoforms [34,35,37].
The analysis of THPO mRNA isoforms in human carcinomas has
shown a different expression pattern of the different splicing variants
[38]. The observation that the mRNAs of major THPO isoforms are
translated suggests that those species are truly functional. Since the
altered splicing proﬁle is already used as indicator of tumor formation
or progression for other genes, such as WT1 or CD44 [39], the pattern
of the THPO alternative splicing might represent a marker useful to
follow tumor progression.
Furthermore, other reports have described the presence and
turnover of the THPO mRNA in normal and neoplastic ovarian cells
[8,40]. It has also been shown that THPO affects directly ovarian
functions by modulating proliferation, apoptosis, secretion of steroid
and peptide hormones, growth factors, as well as by affecting the
expression of some intracellular messengers in porcine ovarian cells
[41].d exon 7 spliced out in themature mRNA are shown by brackets. The C-terminal protein
Table 1
Expression, location and function of the main THPO splicing isoforms
Splicing
variant
Expression Location Function
THPO 1 Lv, Kd,
SM, Pl
Sp, Ts, Ov, FL
Secreted PA [6,35]
BM Inhibits megakaryocyte
apoptosis [55]
Bra [10,11] Proapoptotic [43]
Inhibits NGF-induced
neuronal differentiation
and ERK signaling [56]
Ccc [38]
THPO 2 Lv, Kd, Bra, Ccc Poorly secreted No PA [6,35],
negative regulation?
THPO 3 Lv, Kd, Bra, Ccc Poorly secreted No PA [31],
negative regulation?
THPO 4 Lv, Kd, Bra, Ccc Poorly secreted PA [34]
THPO 5 Lv, Kd, Bra, Ccc Poorly secreted No PA [38],
negative regulation?
THPO 6 Lv, Kd, Bra, Ccc Poorly secreted No PA [38],
negative regulation?
THPO ΔEx2 Lv, Kd, Bra, Ccc Secreted PA [28]
THPO+85 Ccc [51] ? ?
PA, Proliferative Activity.
Liver, Lv. Kidney, Kd. Skeletal Muscle, SM. Placenta, Pl. Spleen, Sp. Testis, Ts. Ovary, Ov.
Fetal Lung, FL. Bone Marrow, BM. Brain, Br. Carcinoma cell lines, Ccc.
a Detected in the following areas: spinal cord; cerebellum; ganglia of the brain stem;
pituitary gland; hippocampus; corpora amygdala; cortex cerebri.
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highlighted that its expression can occur also in tissues not directly
related to the thrombopoiesis. It is intriguing that THPO is also
expressed in the brain and that the relative amounts of its splice
variants (THPO-2, THPO-3, THPO-5 and THPO-6) in developing CNS
are different from those present in adult CNS and liver [10–12].
Concerning the possible biological activities of THPO in the CNS, it has
been demonstrated that c-mlp is expressed in the human brain [42]
and a recent report has shown that THPO counteracts in the brain the
neuroprotective effects of erythropoietin (EPO) [43]. The expression of
neuronal THPO is most prominent in postnatal brain, and, upon
hypoxia, is downregulated along with its receptor. This study has
found that THPO is strongly pro-apoptotic in the brain, causing death
of newly generated neurons [11].
In sum, it is apparent that the expression and the functions of the
THPO mRNA and of its splice variants are wider and more complex
than initially thought (Table 1). Hence, the splicing isoforms of theFig. 2. Structure of the ﬁrst 4 exons and alternative splicing of the human THPO 5′-UTR. Sol
events. Exons are drawn as boxes. uAUG within the THPO 5′-UTR are shown in boldface. ThTHPO carboxy-terminal domain seem to be involved in modulation of
several biological functions beyond thrombopoiesis.
3. Alternative splicing of the 5′ UTR and N-terminus of THPO
mRNA as an additional mechanisms of translational control for
production of this cytokine
Upstream AUGs (uAUGs) and upstream open reading frames
(uORFs) are common features of mRNAs that encode regulatory
proteins and have been shown to profoundly inﬂuence translation of
the main ORF [44–46]. THPO mRNA represents a further example in
which translation normally initiates from an internal position via an
inefﬁcient reinitiation mechanism [28,47]. The 5′ UTR sequence of the
longest THPO mRNA transcript contains seven upstream AUG (uAUG)
codons, whereas the alternative THPO isoforms display a reduced
number and different composition of uAUG codons [30] (Fig. 2).
Recent studies have shown that the uORF-containing THPO mRNA
escapes Nonsense Mediated Decay [48] and mutations that restruc-
ture this mRNA in ways that increase production of thrombopoietin
have shown to cause hereditary thrombocythaemia. These observa-
tions demonstrated that uAUG codons preclude efﬁcient translation
and thus prevent harmful overproduction of potent proteins
[29,30,49]. Two alternative splicing events encompass the 5′ UTR
and the N-terminal of THPO mRNA. The THPO 5′ UTR is encoded by
exons 1, 2 and most of exon 3 and studies on the translational efﬁ-
ciency of THPO have shown that its mRNA is transcribed from two
promoters so generating two major mRNAs (the ﬁrst starting from
exon 1 and the second starting from exon 2) as well as an alternatively
spliced isoform devoid of exon 2 [14,31,47,50]. In particular, it has been
found that the THPO transcript with exon 2 skipping is translated
more efﬁciently into THPO protein than full-length mRNAs [47].
Since alternative splicing does not change the abundance of total
THPO mRNA, it is plausible that the shift of splicing towards a more-
translationally-efﬁcient THPOmRNA isoformsmight increase the serum
levels of this cytokine in many patients with reactive thrombocytosis
and, thus, represent an additional mechanism of regulation of platelet
production [47]. Recent studies on THPO pre-mRNA processing have
identiﬁed an alternative spliced isoform corresponding to a messenger
generated by the activation of a cryptic 3′ splice site within intron 3 and
carrying a 85nt-insertion (Genbank accession number AB102892, THPO
+85 isoform, Fig. 3) [51]. The THPO+85 species presents a shift in the
reading frame after codon 4 leading to a premature stop codon after
codon 56 and might interfere with the production of the THPO-1
isoform, as suggested for the THPOvariant carryingexon2 skipping [29].
These studies have found that evolutionary conserved G-rich splicingid lines connecting exons indicate normal splice events, dashed lines alternative splice
e gray arrow marks the position of the translation initiation codon for THPO.
Fig. 3.Nucleotide and deduced aminoacidic sequences of thewild-type and the THPO+85 alternatively spliced THPO isoforms. The activation of the cryptic acceptor sitewithin intron
3 causes the inclusion of 85 nt in the mature THPOmRNA (THPO+85). The wild-type sequence is reported for comparison purposes (THPO-wt). Upper case, exon 3 and exon 4. Lower
case, intron 3.
Fig. 4. Evolutionary comparison of the human splicing control elements in THPO intron 3 from different species. The alignment of intron 3 from different species was generated using
the GeneBee method (http://www.genebee.msu.ru/genebee.html). The intronic Guanosine rich elements in human intron 3 are underlined. The human cryptic 3′ splice site between
G8 and G9 runs is boxed. Conserved (“+”) and unconserved (“.”) nucleotides are indicated.
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splice site, and thus favour the selection of the authentic acceptor splice
sites of exon 4 and the synthesis of a functional mRNA. Interestingly,
similar SCEs were found to be important to prevent pathological events
in other genes and support the importance of the evolutionary
conservation of these sequences for preservation of gene and protein
function [51–53].
On the other hand, the evolutionary conservation of a particular
gene structure as well as of a speciﬁc splice isoform is generally a good
indicator of the functionality of that variant [54]. Indeed, the
comparison of the structure of THPO gene in different species has
outlined that the THPO IVS3 is substantially conserved in different
species (Fig. 4) [51]. Furthermore, the search in EST databases has
conﬁrmed the presence of THPO+85 variant in rat (Genbank accession
numbers BC078802 and CK471411). Thus, the alternative splicing of
the 5′ UTR as well as of the N-terminus of THPO mRNA in humans
might be part of the peculiar circuit that control the expression of the
THPO protein (Table 1). In conclusion, the expression of THPO in
tissues not directly related to thrombopoiesis as well as in tumors
suggests that THPOmight have yet unknown cellular functions related
to cell cycle and apoptosis. Therefore, the deﬁnition of the biological
function of THPO splicing variants might help for a better character-
ization of the mechanisms controlling protein expression as well as of
the novel roles of this strong cytokine.
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